Harmony Biosciences Holdings
NASDAQ: HRMY · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-04-30
Harmony Biosciences Holdings (HRMY) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for HRMY.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
HRMY historical valuation range
Where current P/E sits in HRMY's own 5Y range.
HRMY intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
HRMY valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 11.46x
P/S Ratio — History
Current: 2.07x
Is HRMY overvalued in 2026?
Harmony Biosciences Holdings (HRMY) currently trades at $31.26 per share with a market capitalization of $1,796,782,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 57/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 11.5x, below its 5-year median of 13.7x.
Looking at its own history, HRMY is currently trading cheaper than 64% of the last 5Y on P/E. This places it in the 36th percentile of its historical range, a reasonable but unremarkable position.
Our discounted cash flow model estimates HRMY's intrinsic value at $64.38 per share, against the current market price of $31.26. This implies a margin of safety of +43.17%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: HRMY trades at a fair valuation on our framework, with a Smart Value Score of 57/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is HRMY overvalued in 2026?
Based on a Smart Value Score of 57/100, HRMY is fairly valued. Price reasonably reflects current fundamentals with limited cushion in either direction.
What is HRMY's fair value?
Our DCF model estimates HRMY's intrinsic value at $64.38 per share, versus the current price of $31.26. This produces a margin of safety of +43.17%.
What P/E ratio does HRMY trade at?
HRMY trades at a P/E of 11.5x on trailing twelve-month earnings, compared to its 5-year median of 13.7x.
Is HRMY a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 57/100 reflects the combined read on growth, quality, and price. The profile is balanced. Best suited for investors with an existing thesis.
How does HRMY's valuation compare to its history?
On P/E, HRMY currently sits in the 36th percentile of its own 5Y range. That is below its long-run median relative to where it has traded over the period.
What is HRMY's Smart Value Score?
HRMY's Smart Value Score is 57/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.